EZZ Life Science Holdings Ltd. (EZZ) AI Stock Analysis

• Market Cap: AU$75.24M
• Dividend Yield: 2.19%
• Average Volume (3M): 38.16K
• Price to Earnings (P/E): 7.8
• Beta (1Y): -0.21
• Revenue Growth: 71.65%
• EPS Growth: 152.89%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.20
• Shares Outstanding: 47,173,200
• 10 Day Avg. Volume: 45,013
• 30 Day Avg. Volume: 38,157
• PEG Ratio: 0.28
• Price to Book (P/B): 2.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 8.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

EZZ Life Science Holdings Ltd. scores well due to its robust financial performance, characterized by strong revenue growth, solid profit margins, and excellent cash flow generation. The valuation is appealing with a low P/E ratio and a decent dividend yield. However, technical analysis indicates some caution due to potential resistance and overbought conditions. Overall, the stock is fundamentally strong but faces some technical headwinds.

EZZ Life Science Holdings Ltd. Business Overview & Revenue Model

Company Description

EZZ Life Science Holdings Ltd. (EZZ) is an Australian life sciences company operating in the health and wellness sector. The company specializes in the development, marketing, and distribution of consumer health products, with a strong focus on nutritional and dietary supplements. EZZ leverages scientific research and innovation to create products that support health improvement and disease prevention, catering to a growing demand for health and wellness solutions.

How the Company Makes Money

EZZ Life Science Holdings Ltd. generates revenue primarily through the sale of its health and wellness products, including nutritional and dietary supplements. These products are distributed through various channels, including direct sales to consumers, partnerships with retailers, and e-commerce platforms. The company's revenue streams are diversified across multiple markets, with a significant presence in Australia and expansion efforts targeting international markets. In addition to product sales, EZZ may engage in strategic partnerships or collaborations with other companies within the life sciences sector, contributing to its earnings through shared research and development initiatives or joint marketing efforts.

EZZ Life Science Holdings Ltd. Financial Statement Overview

Summary

EZZ Life Science Holdings Ltd. exhibits strong financial health across all verticals. The income statement reflects significant revenue and profit growth, supported by efficient operational management. The balance sheet reveals a solid equity base with minimal leverage, enhancing financial stability. Cash flow metrics display substantial cash generation, underlining the company's robust cash management practices. Overall, EZZ Life Science is well-positioned for growth with strong fundamentals.

Income Statement

EZZ Life Science Holdings Ltd. demonstrates strong revenue growth, with a 78.9% increase in total revenue from 2023 to 2024. The gross profit margin is robust at 74.2%, indicating efficient cost management. Net profit margin stands at 10.5%, showing healthy profitability, though there's room for improvement in converting revenue to net income. EBIT and EBITDA margins are solid at 14.6% and 15.6%, respectively, reflecting operational efficiency.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.01, showcasing a conservative leverage strategy. Return on Equity (ROE) is strong at 32.7%, indicating effective use of shareholders' equity. The equity ratio is high at 83.5%, highlighting financial stability and low financial risk. Overall, the balance sheet reflects a strong financial position with minimal debt.

Cash Flow

EZZ Life Science Holdings Ltd. shows a significant increase in free cash flow, with a growth rate of 46.6% from the previous year. The operating cash flow to net income ratio is 0.88, indicating efficient cash generation relative to reported earnings. The free cash flow to net income ratio is 0.82, suggesting that the company's operations are generating ample cash relative to net income.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
75.03M	66.44M	37.14M	15.02M	22.29M	17.32M
	Gross Profit
58.04M	50.95M	27.20M	7.51M	12.46M	3.56M
	EBIT
14.01M	9.72M	4.62M	1.78M	2.75M	1.48M
	EBITDA
13.45M	10.38M	5.09M	1.90M	2.76M	2.30M
	Net Income Common Stockholders
9.02M	6.96M	3.63M	1.31M	2.03M	1.59M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
19.89M	19.02M	13.83M	10.46M	8.85M	8.41M
	Total Assets
29.74M	25.55M	17.64M	14.27M	12.04M	11.63M
	Total Debt
478.59K	123.86K	478.59K	104.57K	79.01K	32.00K
	Net Debt
-19.41M	-18.90M	-13.35M	-10.36M	-8.77M	-8.38M
	Total Liabilities
5.70M	4.23M	3.06M	2.88M	1.93M	3.78M
	Stockholders Equity
24.04M	21.32M	14.58M	11.39M	10.11M	7.85M
Cash Flow		Free Cash Flow
7.40M	5.73M	3.91M	1.89M	237.42K	2.88M
	Operating Cash Flow
7.97M	6.14M	4.01M	1.90M	253.53K	2.97M
	Investing Cash Flow
-425.39K	-441.17K	-101.78K	-13.18K	-16.12K	-91.20K
	Financing Cash Flow
-1.03M	-582.45K	-761.72K	-277.36K	5.44M	-122.25K

EZZ Life Science Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.60
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Positive. The current price of 1.6 is above the 20-day moving average (MA) of 1.49, above the 50-day MA of 1.50, and below the 200-day MA of 2.42, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.56 is Neutral, neither overbought nor oversold. The STOCH value of 79.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EZZ.

EZZ Life Science Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	71 Outperform	AU$75.24M	7.76	45.86%	2.19%	71.65%	152.89%
CSL	64 Neutral	$117.09B	28.10	15.38%	1.74%	8.00%	9.09%
RAC	54 Neutral	AU$251.04M	―	-37.20%	―	―	32.02%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
MSB	46 Neutral	$2.21B	―	-21.31%	―	―	―
CYC	45 Neutral	AU$132.81M	―	-35.20%	―	4.68%	-155.42%
OPT	30 Underperform	$738.77M	―		―	-24.46%	-7.90%

EZZ Life Science Holdings Ltd. Corporate Events

EZZ Life Science Holdings Announces Dividend Distribution

EZZ Life Science Holdings Ltd. has announced a dividend distribution of AUD 0.02 per ordinary fully paid share, covering the six-month period ending December 31, 2024. The ex-dividend date is set for May 16, 2025, with the record date on May 19, 2025, and payment scheduled for June 17, 2025. This announcement reflects the company’s financial health and commitment to returning value to shareholders, potentially strengthening its market position and investor confidence.

EZZ Life Science Declares Interim Dividend for 2024

EZZ Life Science Holdings Limited has announced a fully franked interim dividend of $0.020 per share for the half year ending 31 December 2024. This decision reflects the company’s commitment to rewarding shareholders and may enhance investor confidence. The dividend will be paid on 17 June 2025, with the ex-dividend date set for 16 May 2025 and the record date on 19 May 2025.

EZZ Life Science Reports Strong Q3 Performance and Strategic Growth Initiatives

EZZ Life Science Holdings Limited reported strong operational performance for the quarter ending March 31, 2025, despite a decline in customer receipts due to seasonal factors and reduced digital advertising. The company achieved a positive cash inflow of $1.5 million and maintained a record cash reserve of $21.1 million. EZZ launched two new products and upgraded three existing ones, enhancing its competitive position. The company expanded its domestic distribution and made strategic progress in entering the US market. EZZ also increased brand visibility through sponsorships and strengthened its presence in China, positioning itself for long-term growth.

EZZ Life Science Expands into North America with New Manufacturing Partnership

EZZ Life Science Holdings Ltd has entered into a manufacturing agreement with GLSP Inc. to produce dietary supplements in the United States, marking a significant milestone in its North American expansion strategy. This partnership is expected to enhance production efficiencies, improve supply chain logistics, and strengthen EZZ’s market positioning in the region, aligning with the company’s strategy to meet the growing demand for high-quality, science-backed health supplements.

EZZ Life Science Holdings Ltd. Issues 1H FY25 Results Webinar Disclaimer

EZZ Life Science Holdings Ltd. has released a document concerning its 1H FY25 results webinar. The document serves as a disclaimer and cautionary note for investors, emphasizing that it is not a prospectus or offer document and does not provide investment advice. It highlights the presence of forward-looking statements and the associated risks, urging investors to conduct their own assessments and seek professional advice before making investment decisions.

EZZ Life Science Reports Strong Half-Year Financial Performance

EZZ Life Science Holdings Limited reported a significant increase in both revenue and profit for the half-year ending December 31, 2024. Revenues rose by 39.6% to over $30 million, while profits surged by nearly 180% to approximately $3.2 million, attributed to increased marketing expenditures. The company’s EBITDA also saw a substantial rise, indicating strong operational performance. The announcement highlights EZZ Life Science’s robust financial health and strategic market positioning, which could positively impact stakeholders and enhance its competitive edge in the industry.